The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer

Reviews in Urology

David Albala¹  Robert B Sims⁴  Neil Mariados²  Raoul S Concepcion¹  Mark Emberton³  Neal D Shore⁵  Vladimir Mouraviev²  Christopher M Pieczonka² 

[1] Urology Associates,, Nashville, TN;Associated Medical Professionals of New York,, Syracuse, NY;University College of London,, London, UK;Dendreon Corporation,, Seattle, WA;Carolina Urologic Research Center, 21st Century Oncology,, Myrtle Beach, SC

关键词: Combination therapy;    Prostate cancer;    Sipuleucel-T;   

DOI  :  

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

Immunotherapy encourages the recipient’s own immune response to destroy cancer cells, and current evidence suggests that immunotherapies may be most beneficial in early metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T is the first therapeutic cancer vaccine to be approved by both the US Food and Drug Administration and European Medicines Agency for the treatment of asymptomatic or minimally symptomatic mCRPC. Combining immunotherapy with other treatments may have potent anticancer effects; cytoreductive therapies can release tumor antigens and promote a proinflammatory environment that could augment immunotherapies. However, some cytoreductive agents or coadministered drugs may be immunosuppressive. Understanding these interactions between different mCRPC treatment modalities may offer further potential to improve patient outcomes.

【 授权许可】

Unknown